Dynamic nuclear spin polarization (DNP), in which polarization is transferred from electron to nuclear spins at low temperature and high magnetic field, has a long history, with the first experiments being performed in the 1950s [1]. However, it was not until 2003, when it was shown that molecules containing hyperpolarized 13C spins at ~ 1.2 K could be rapidly warmed to room temperature, with substantial retention of this nuclear spin polarization [2], that the power of this technology was unleashed for solution state NMR studies. A major focus has been on metabolic imaging with hyperpolarized 13C-labeled cell substrates, where the > 104 gain in sensitivity has enabled 13C magnetic resonance spectroscopic (MRSI) imaging of injected hyperpolarized 13C-labelled substrates (probes) in the body and their biochemical conversion to metabolic products. Basic and preclinical research leveraging these hyperpolarized probes (reviewed in [3,4,5,6]), culminated in translation of this approach to the clinic with a study of hyperpolarized [1-13C]pyruvate metabolism in prostate cancer [7]. The technique now stands on the threshold of wider clinical application with the publication of further studies in prostate cancer [8,9,10,11,12], and initial studies of hyperpolarized [1-13C]pyruvate metabolism in brain [13, 14] and heart tissue [15, 16] and in tumors of the brain [17,18,19,20], breast [21, 22], pancreas [23] and kidney [24]. An alternative approach to hyperpolarizing 13C spins, which is reviewed in this issue, is to transfer spin order from parahydrogen. The advantage of this method is that the equipment is less expensive and polarization times are much shorter, allowing for semi-continuous production. However, the levels of polarization achieved in molecules of immediate interest, such as pyruvate, are much lower and although [1-13C]pyruvate polarized using this method has been used in vivo the technique is at a much earlier stage on the path to clinical translation.
[1-13C]pyruvate has been the most widely used substrate as it can be polarized to high levels (> 60% at 7T [25]) with sufficiently long 13C T1 relaxation times in vivo to facilitate metabolic imaging. The door is now open to pursue many new probes but as the field is consolidating, it faces 2 major challenges: (1) What is the role of this imaging modality in the management of disease? (2) Can some of the technical hurdles facing hyperpolarized MRI be overcome in order to facilitate widespread use of this approach.
-
1.
Preclinical and recent clinical studies have suggested that hyperpolarized metabolic imaging can provide a non-radioactive approach to assess tumor grade, progression and treatment response [8, 11, 12, 19, 22]. Beyond cancer, this has further been exemplified in highly metabolic organs including studies in the brain and heart, where understanding disease can be unlocked by flux measurements using HP MRI. The technique has not the breadth of nuclear medicine imaging, but then this has a history of more than 50 years in patients. In order to progress the field, many more studies are required to truly say something relevant about human biology, though current technical limitations preclude such studies from being achieved.
-
2.
While high polarizations have been achieved for substrates at high concentration, current approaches are limited due to low throughput, long polarization times and challenges with respect to final concentrations. New developments highlighted in this special issue provide dramatic improvements in both polarization methodologies and the ability to separate polarization from dissolution. These strategies can reduce the technical burdens of hyperpolarization and could facilitate its application to clinical studies. Further, many imaging approaches have been designed to encode these rapidly decaying and interconverting signals. Uniformity across platforms is required to be able to compare such data. In an effort to get closer to consensus, reviews from experts in hyperpolarized imaging are needed which compare the strengths and weaknesses of these imaging strategies.
While these technical hurdles must be overcome to truly address the needs of the field, the future is encouraging and new developments are paving the way to a more holistic view of metabolism in vivo.
References
Overhauser AW (1953) Polarization of nuclei in metals. Phys Rev 92(2):411
Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K (2003) Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc Natl Acad Sci USA 100(18):10158–10163
Keshari KR, Wilson DM (2014) Chemistry and biochemistry of 13C hyperpolarized magnetic resonance using dynamic nuclear polarization. Chem Soc Rev 43(5):1627–1659. https://doi.org/10.1039/c3cs60124b
Comment A, Merritt ME (2014) Hyperpolarized magnetic resonance as a sensitive detector of metabolic function. Biochemistry 53(47):7333–7357. https://doi.org/10.1021/bi501225t
Brindle KM (2015) Imaging metabolism with hyperpolarized 13C-labeled cell substrates. J Am Chem Soc 137(20):6418–6427
Hesketh RL, Brindle KM (2018) Magnetic resonance imaging of cancer metabolism with hyperpolarized 13C-labeled cell metabolites. Curr Opin Chem Biol 45:187–194. https://doi.org/10.1016/j.cbpa.2018.03.004
Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PEZ, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, Small EJ, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, Chen AP, Hurd RE, Odegardstuen L-I, Robb FJ, Tropp J, Murray JA (2013) Metabolic imaging of patients with prostate cancer using hyperpolarized [1–13C]pyruvate. Sci Transl Med 5(198):19ra108. https://doi.org/10.1126/scitranslmed.3006070
Aggarwal R, Vigneron DB, Kurhanewicz J (2017) Hyperpolarized [1-13C]-pyruvate magnetic resonance imaging detects an early metabolic response to androgen ablation therapy in prostate cancer. Eur Urol 72(6):1028–1029. https://doi.org/10.1016/j.eururo.2017.07.022
Chen H-Y, Larson PEZ, Gordon JW, Bok RA, Ferrone M, van Criekinge M, Carvajal L, Cao P, Pauly JM, Kerr AB, Park I, Slater JB, Nelson SJ, Munster PN, Aggarwal R, Kurhanewicz J, Vigneron DB (2018) Technique development of 3D dynamic CS-EPSI for hyperpolarized (13) C pyruvate MR molecular imaging of human prostate cancer. Magn Reson Med 80(5):2062–2072. https://doi.org/10.1002/mrm.27179
Larson PEZ, Chen HY, Gordon JW, Korn N, Maidens J, Arcak M, Tang S, Criekinge M, Carvajal L, Mammoli D, Bok R, Aggarwal R, Ferrone M, Slater JB, Nelson SJ, Kurhanewicz J, Vigneron DB (2018) Investigation of analysis methods for hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients. NMR Biomed 31(11):e3997. https://doi.org/10.1002/nbm.3997
Chen H-Y, Aggarwal R, Bok RA, Ohliger MA, Zhu Z, Lee P, Gordon JW, van Criekinge M, Carvajal L, Slater JB, Larson PEZ, Small EJ, Kurhanewicz J, Vigneron DB (2020) Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. Prostate Cancer Prostat Dis 23(2):269–276. https://doi.org/10.1038/s41391-019-0180-z
Granlund KL, Tee S-S, Vargas HA, Lyashchenko SK, Reznik E, Fine S, Laudone V, Eastham JA, Touijer KA, Reuter VE, Gonen M, Sosa RE, Nicholson D, Guo YW, Chen AP, Tropp J, Robb F, Hricak H, Keshari KR (2020) Hyperpolarized MRI of human prostate cancer reveals increased lactate with tumor grade driven by monocarboxylate transporter 1. Cell Metab 31(1):105-114.e103. https://doi.org/10.1016/j.cmet.2019.08.024
Grist JT, McLean MA, Riemer F, Schulte RF, Deen SS, Zaccagna F, Woitek R, Daniels CJ, Kaggie JD, Matys T, Patterson I, Slough R, Gill AB, Chhabra A, Eichenberger R, Laurent MC, Comment A, Gillard JH, Coles AJ, Tyler DJ, Wilkinson I, Basu B, Lomas DJ, Graves MJ, Brindle KM, Gallagher FA (2019) Quantifying normal human brain metabolism using hyperpolarized 1-C-13 pyruvate and magnetic resonance imaging. Neuroimage 189:171–179. https://doi.org/10.1016/j.neuroimage.2019.01.027
Lee CY, Soliman H, Geraghty BJ, Chen AP, Connelly KA, Endre R, Perks WJ, Heyn C, Black SE, Cunningham CH (2020) Lactate topography of the human brain using hyperpolarized 13C-MRI. NeuroImage 204:116202. https://doi.org/10.1016/j.neuroimage.2019.116202
Cunningham CH, Lau JY, Chen AP, Geraghty BJ, Perks WJ, Roifman I, Wright GA, Connelly KA (2016) Hyperpolarized 13C metabolic MRI of the human heart: initial experience. Circ Res 119(11):1177–1182. https://doi.org/10.1161/circresaha.116.309769
Rider OJ, Apps A, Miller J, Lau JYC, Lewis AJM, Peterzan MA, Dodd MS, Lau AZ, Trumper C, Gallagher FA, Grist JT, Brindle KM, Neubauer S, Tyler DJ (2020) Noninvasive in vivo assessment of cardiac metabolism in the healthy and diabetic human heart using hyperpolarized 13C MRI. Circ Res 126(6):725–736. https://doi.org/10.1161/circresaha.119.316260
Park I, Larson PEZ, Gordon JW, Carvajal L, Chen HY, Bok R, Van Criekinge M, Ferrone M, Slater JB, Xu D, Kurhanewicz J, Vigneron DB, Chang S, Nelson SJ (2018) Development of methods and feasibility of using hyperpolarized carbon-13 imaging data for evaluating brain metabolism in patient studies. Magn Reson Med 80(3):864–873. https://doi.org/10.1002/mrm.27077
Miloushev VZ, Granlund KL, Boltyanskiy R, Lyashchenko SK, DeAngelis LM, Mellinghoff IK, Brennan CW, Tabar V, Yang TJ, Holodny AI, Sosa RE, Guo YW, Chen AP, Tropp J, Robb F, Keshari KR (2018) Metabolic imaging of the human brain with hyperpolarized 13C pyruvate demonstrates 13C lactate production in brain tumor patients. Can Res. https://doi.org/10.1158/0008-5472.can-18-0221
Autry AW, Gordon JW, Chen H-Y, LaFontaine M, Bok R, Van Criekinge M, Slater JB, Carvajal L, Villanueva-Meyer JE, Chang SM, Clarke JL, Lupo JM, Xu D, Larson PEZ, Vigneron DB, Li Y (2020) Characterization of serial hyperpolarized 13C metabolic imaging in patients with glioma. NeuroImage Clin 27:102323. https://doi.org/10.1016/j.nicl.2020.102323
Mammoli D, Gordon J, Autry A, Larson PEZ, Li Y, Chen HY, Chung B, Shin P, Van Criekinge M, Carvajal L, Slater JB, Bok R, Crane J, Xu D, Chang S, Vigneron DB (2020) Kinetic modeling of hyperpolarized carbon-13 pyruvate metabolism in the human brain. IEEE Trans Med Imaging 39(2):320–327. https://doi.org/10.1109/tmi.2019.2926437
Gallagher FA, Woitek R, McLean MA, Gill AB, Manzano Garcia R, Provenzano E, Riemer F, Kaggie J, Chhabra A, Ursprung S, Grist JT, Daniels CJ, Zaccagna F, Laurent M-C, Locke M, Hilborne S, Frary A, Torheim T, Boursnell C, Schiller A, Patterson I, Slough R, Carmo B, Kane J, Biggs H, Harrison E, Deen SS, Patterson A, Lanz T, Kingsbury Z, Ross M, Basu B, Baird R, Lomas DJ, Sala E, Wason J, Rueda OM, Chin S-F, Wilkinson IB, Graves MJ, Abraham JE, Gilbert FJ, Caldas C, Brindle KM (2020) Imaging breast cancer using hyperpolarized carbon-13 MRI. Proc Natl Acad Sci 117(4):2092–2098. https://doi.org/10.1073/pnas.1913841117
Woitek R, McLean MA, Gill AB, Grist JT, Provenzano E, Patterson AJ, Ursprung S, Torheim T, Zaccagna F, Locke M, Laurent M-C, Hilborne S, Frary A, Beer L, Rundo L, Patterson I, Slough R, Kane J, Biggs H, Harrison E, Lanz T, Basu B, Baird R, Sala E, Graves MJ, Gilbert FJ, Abraham JE, Caldas C, Brindle KM, Gallagher FA (2020) Hyperpolarized 13C MRI of tumor metabolism demonstrates early metabolic response to neoadjuvant chemotherapy in breast cancer. Radiol Imaging Cancer 2(4):e200017. https://doi.org/10.1148/rycan.2020200017
Stødkilde-Jørgensen H, Laustsen C, Hansen ESS, Schulte R, Ardenkjaer-Larsen JH, Comment A, Frøkiaer J, Ringgaard S, Bertelsen LB, Ladekarl M, Weber B (2020) Pilot Study Experiences With Hyperpolarized [1-(13) C]pyruvate MRI in Pancreatic Cancer Patients. J Magn Reson Imaging JMRI 51(3):961–963. https://doi.org/10.1002/jmri.26888
Tran M, Latifoltojar A, Neves JB, Papoutsaki M-V, Gong F, Comment A, Costa ASH, Glaser M, Tran-Dang M-A, El Sheikh S, Piga W, Bainbridge A, Barnes A, Young T, Jeraj H, Awais R, Adeleke S, Holt C, O’Callaghan J, Twyman F, Atkinson D, Frezza C, Årstad E, Gadian D, Emberton M, Punwani S (2019) First-in-human in vivo non-invasive assessment of intra-tumoral metabolic heterogeneity in renal cell carcinoma. BJR Case Rep 5(3):20190003. https://doi.org/10.1259/bjrcr.20190003
Yoshihara HAI, Can E, Karlsson M, Lerche MH, Schwitter J, Comment A (2016) High-field dissolution dynamic nuclear polarization of [1-13C]pyruvic acid. Phys Chem Chem Phys 18(18):12409–12413. https://doi.org/10.1039/C6CP00589F
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
KMB has research agreements with GE Healthcare and holds patents with them on some aspects of DNP technology. KRK has research agreements with GE Healthcare and holds patents with them on some aspects of DNP technology. Further disclosures can be found at https://www.mskcc.org/research-areas/labs/kayvan-keshari#disclosures.
Ethical statement
This article does not describe any primary research and therefore an ethical statement is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Brindle, K.M., Keshari, K.R. Editorial commentary for the special issue: technological developments in hyperpolarized 13C imaging—toward a deeper understanding of tumor metabolism in vivo. Magn Reson Mater Phy 34, 1–3 (2021). https://doi.org/10.1007/s10334-021-00908-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10334-021-00908-1